Another study showed that a miRNA signature classifier (MSC) consisting of 24 miRNAs could distinguish NSCLC patients who benefited from anti-PD-L1 immunotherapy from those who did not benefit [146]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.